Découvrez nos professeurs et professeures!

Revenir au répertoire
Fiche précédente
Fiche suivante

Jacques Simard

Professeur titulaire

Jacques Simard
jacques.simard@fmed.ulaval.ca
Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :

Contribution à la recherche

Axe de recherche de l'Université Laval :

Santé et bien-être durables

Thématiques de recherche de la Faculté de médecine :

Oncologie
Santé des populations et pratiques optimales en santé
Bioinformatique / données massives (big data)
Transfert des connaissances

Domaines et intérêts de recherche du (de la) professeur(e) :

Cancer
  • Cancer du sein
  • Cancer héréditaire
  • Cancers hormonaux-dépendants
  • Génétique du cancer
Génétique humaine
  • Gènes de susceptibilité
  • Génétique et éthique
  • Génétique moléculaire
  • Génomique
  • Polymorphisme
Santé des populations
Services de santé
Génomique et protéomique

Projets de recherche

  • Characterization of novel breast cancer susceptibility genes through large-scale targeted sequencing and functional assays. - Instituts de recherche en santé du Canada - Subvention Projet, chercheur principal - 2024-04-01 au 2029-03-31
  • Caractérisation de nouveaux gènes de susceptibilité au cancer du sein - Ministère de l'Économie et de l'Innovation et de l'énergie - Programme de soutien aux organismes de recherche et d’innovation (PSO) - International Volet 2C(Ancien PSR-SIIRI), chercheur principal - 2024-02-15 au 2027-04-01
  • Grand Prix Scientifique 2024 de la Fondation du cancer du sein du Québec - Fondation du cancer du sein du Québec - Prix d'excellence - Grand prix scientifique, chercheur principal - 2024-03-31 au 2025-03-31
  • Fonds institutionnel d'exploitation des infrastructures pour l'Université Laval - Fondation Canadienne pour l'innovation (La) - Fonds d'exploitation des infrastructures (FEI), co-chercheur - 2002-04-01 au 2025-03-31
  • Journées de la recherche de la Faculté de médecine et des centres de recherche - Université Laval - Fonds internes - BDR - Contributions, chercheur principal - 2023-04-17 au 2024-04-30
  • Observatoire international sur les impacts sociétaux de l'intelligence artificielle et du numérique - Fonds de recherche du Québec - Société et culture, Université Laval - Fonds internes - Appel à propositions : création d’un Observatoire international sur les impacts sociétaux de l’intelligence artificielle et du numérique, co-chercheur - 2018-04-01 au 2024-03-31
  • The contribution of RAD51C and RAD51D to breast and ovarian cancer - National Institute of Health (USA) - Subvention de recherche, Mayo Clinic Rochester, co-chercheur - 2021-05-01 au 2023-04-30
  • From correlation to causation in genomics: identifying mechanisms underlying disease - Instituts de recherche en santé du Canada - Subventions Fondation, University of Toronto, co-chercheur - 2015-07-01 au 2022-06-30
  • Chaire de recherche du Canada en oncogénétique - Instituts de recherche en santé du Canada - Chaires de recherche du Canada - Fonctionnement, chercheur principal - 2015-03-01 au 2022-06-30
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) - Regroupement de compagnies et corporations canadiennes, Fondation du CHU de Québec, Génome Québec, Ministère de la santé (Ontario), Ministère de l'Économie, de la Science et de l'Innovation, Instituts de recherche en santé du Canada, Fondation du cancer du sein du Québec, Génome Canada - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 1.1 - Génome Québec, Instituts de recherche en santé du Canada - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 5 - Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activités 3.1/3.2 - Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 3.3 - Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 1.2 - Instituts de recherche en santé du Canada, Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : R92 - Transferts de fonds interinstitutions - Génome Québec, Instituts de recherche en santé du Canada - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Quand innovations technologique et organisationnelle vont de pair: Un modèle collaboratif pour rendre l'oncogénétique plus agile, accessible et efficiente - Fonds de recherche du Québec - Santé, co-chercheur - 2020-04-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 2.3 - Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31

Publications

  • Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23-->p22, , Cytogenet Cell Genet, 1996, 10.1159/000134362
  • Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSD, , Biochemistry, 1995, 10.1021/bi00009a020
  • Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes, , Nat Genet, 2020, 10.1038/s41588-019-0537-1
  • Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells, , Cancer Res, 1997
  • Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer, , Nat Genet, 2015, 10.1038/ng.3242
  • Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells, , Ann N Y Acad Sci, 1990, 10.1111/j.1749-6632.1990.tb34288.x
  • EM-652 (SCH 57068), a pure SERM in the mammary gland and endometrium, , Ref Gynecol Obstet, 2001
  • Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers, , Cancer Epidemiol Biomarkers Prev, 2015, 10.1158/1055-9965.Epi-14-0532
  • Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in normal and tumoral target tissues, , J Steroid Biochem Mol Biol, 2001, 10.1016/s0960-0760(00)00148-5
  • (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen, , J Med Chem, 1997, 10.1021/jm970095o
  • Molecular cloning of rat 3b-hydroxysteroid dehydrogenase/D5-D4 isomerase: structure of two types of cDNAs and differential expression of the corresponding mRNAs in the ovary (Chapter 28), , Signaling Mechanisms and Gene Expression in the Ovary, 1991
  • Is dehydroepiandrosterone a hormone?, , J Endocrinol, 2005, 10.1677/joe.1.06264
  • Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers, , Cancer Epidemiol Biomarkers Prev, 2012, 10.1158/1055-9965.Epi-11-0888
  • Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers, , Front Genet, 2017, 10.3389/fgene.2017.00128
  • Localization of peripheral benzodiazepine binding sites and diazepam-binding inhibitor (DBI) mRNA in mammary glands and dimethylbenz(a)antracene (DMBA)-induced mammary tumors in the rat, , Regul Pept, 1991, 10.1016/0167-0115(91)90229-a
  • Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk, , PLoS Genet, 2013, 10.1371/journal.pgen.1003212
  • Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention, Lesa Dawson, Jacques Simard, Gavin Stuart, David Huntsman, Ranjit Manchanda, William D. Foulkes, Nora Pashayan, Kelly Metcalfe, Trevor Dummer, Aline Talhouk, Stuart J. Peacock, Kasmintan Schrader, Bartha Knoppers, Gillian E. Hanley, Janice S. Kwon, Michelle Woo, Stephanie Lam, Almira Zhantuyakova, Lauren C. Tindale, Current Oncology, 2022, 10.3390/curroncol29070368
  • Ontogeny and subcellular localization of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) in the human and rat adrenal, ovary and testis, , J Steroid Biochem Mol Biol, 1992, 10.1016/0960-0760(92)90084-v
  • Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation, , J Obstet Gynaecol Can, 2007, 10.1016/s1701-2163(16)32349-0
  • Perceptions and Usability of PREVENTION: A Breast Cancer Risk Assessment e-Platform, Carmen G. Loiselle, Jacques Simard, Bartha M. Knoppers, Saima Ahmed, Andrew Durand, Marika Monarque, Samar Attieh, Journal of Personalized Medicine, 2023, 10.3390/jpm13050850
  • The human type II 17 beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species, , DNA Cell Biol, 1995, 10.1089/dna.1995.14.849
  • Ethical challenges and innovations in the dissemination of genomic data: the experience of the PERSPECTIVE project, , Adv Genomics Genet, 2015
  • Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer, , Int J Cancer, 2016, 10.1002/ijc.30150
  • Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1, , Am J Hum Genet, 2013, 10.1016/j.ajhg.2013.10.026
  • DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology, , Front Neuroendocrinol, 2001, 10.1006/frne.2001.0216
  • Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG, , Prostate, 2012, 10.1002/pros.21443
  • Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer, , Carcinogenesis, 2015, 10.1093/carcin/bgu326
  • Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families, , Fam Cancer, 2007, 10.1007/s10689-007-9151-y
  • Identification of six new susceptibility loci for invasive epithelial ovarian cancer, , Nat Genet, 2015, 10.1038/ng.3185
  • Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry, , EBioMedicine, 2019, 10.1016/j.ebiom.2019.09.006
  • Functional and clinical characterization of variants of uncertain significance identifies a hotspot for inactivating missense variants in RAD51C., Fergus Couch, Yuan-Ping Pang, Jean Yves Masson, Jacques Simard, Steven Hart, Saravut Weroha, Jill Dolinsky, Kathleen Hruska, Siddhartha Yadav, Susan Domchek, Marcy Richardson, Rachid Karam, gaofeng cui, Georges Mer, Eric Polley, Rohan Gnanaolivu, Nicholas Boddicker, Jeffrey Weitzel, Nathanson KL, Irene Ong, Song Yao, Celine Vachon, Lauren Teras, Julie Palmer, Sara Lindstrom, Peter Kraft, Christopher Haiman, Susan Neuhausen, Tina Pesaran, AMAL YUSSUF, Elizabeth, Holly LaDuca, Susan Hiraki, Megan Marshall, Maegan Roberts, Lisa Susswein, jie na, Carolyn Lumby, Huaizhi Huang, Kun Lee, Gemma Montalban, Hermela Shimelis, ANIL BELUR NAGARAJ, Chunling Hu, Cancer research, 2023, 10.1158/0008-5472.can-22-2319
  • Association analysis identifies 65 new breast cancer risk loci, , Nature, 2017, 10.1038/nature24284
  • Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers, , Breast Cancer Res Treat, 2012, 10.1007/s10549-012-2255-6
  • Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction, , Cancer Res, 2010, 10.1158/0008-5472.Can-10-1907
  • Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent, , J Natl Cancer Inst, 2020, 10.1093/jnci/djz109
  • Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk, , Cancer Epidemiol Biomarkers Prev, 2015, 10.1158/1055-9965.Epi-15-0363
  • Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells, , J Steroid Biochem Mol Biol, 2003, 10.1016/j.jsbmb.2003.08.006
  • Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations, , Hum Mol Genet, 1996, 10.1093/hmg/5.6.835
  • Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170, , Nat Genet, 2016, 10.1038/ng.3521
  • Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data, , J Pers Med, 2021, 10.3390/jpm11080726
  • Toward a Population-Based Breast Cancer Risk Stratification Approach? The Needs and Concerns of Healthcare Providers, , J Pers Med, 2021, 10.3390/jpm11060540
  • Flutamide in combination with castration (surgical or medical) is the standard treatment in advanced prostate cancer, , Journal of drug development, 1987
  • No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families, , Genet Test, 2006, 10.1089/gte.2006.10.104
  • Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer, , BMC Cancer, 2009, 10.1186/1471-2407-9-181
  • Genetic predisposition to in situ and invasive lobular carcinoma of the breast, , PLoS Genet, 2014, 10.1371/journal.pgen.1004285
  • Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study, , Cancer Epidemiol Biomarkers Prev, 2009, 10.1158/1055-9965.Epi-08-0546
  • Genome-wide association studies identify four ER negative-specific breast cancer risk loci, , Nat Genet, 2013, 10.1038/ng.2561
  • Reply by the authors to : Editorial Comment of : Comparison of in vitro effects of the pure antiandrogens OH-flutamide, casodex, and nilutamide on androgen-sensitive parameters, , Urology, 1997
  • Structure and sexual dimorphic expression of a liver-specific rat 3 beta-hydroxysteroid dehydrogenase/isomerase, , Endocrinology, 1990, 10.1210/endo-127-6-3237
  • Correction: BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors, , Genet Med, 2019, 10.1038/s41436-019-0459-4
  • Structure-function relationships and molecular genetics of the 3 beta-hydroxysteroid dehydrogenase gene family, , J Steroid Biochem Mol Biol, 1995, 10.1016/0960-0760(95)00198-0
  • ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes, , Hum Mutat, 2012, 10.1002/humu.21628
  • Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues, , Trends Endocrinol Metab, 2000, 10.1016/s1043-2760(00)00342-8
  • Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness, , Cancer Res, 2020, 10.1158/0008-5472.Can-19-1840
  • Localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in rat gonads and adrenal glands by immunocytochemistry and in situ hybridization, , Endocrinology, 1990, 10.1210/endo-127-3-1394
  • Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies, , Curr Oncol, 2016, 10.3747/co.23.2961
  • No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result, , Cancer Epidemiol Biomarkers Prev, 2005, 10.1158/1055-9965.Epi-05-0512
  • Structure and tissue-specific expression of a novel member of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) family. The exclusive 3 beta-HSD gene expression in the skin, , J Biol Chem, 1993
  • EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium, , J Steroid Biochem Mol Biol, 2001, 10.1016/s0960-0760(01)00139-x
  • Guidelines for disclosing genetic information to family members: from development to use, , Fam Cancer, 2006, 10.1007/s10689-005-2581-5
  • DHEA, the precursor of androgens and estrogens in peripheral tissues in the human: intracrinology, , Dehydroepiandrosterone (DHEA): biochemical, physiological and clinical aspects, 2000
  • Androgen receptor antagonists (Chapter 28), , Reproductive endocrinology, surgery, and technology, 1996
  • Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families, , Nat Genet, 1994, 10.1038/ng1294-392
  • AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study, , Cancer Epidemiol Biomarkers Prev, 2007, 10.1158/1055-9965.Epi-07-0129
  • Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling, , Genet Test, 2007, 10.1089/gte.2006.9998
  • Using Real-World Data to Determine Health System Costs of Ontario Women Screened for Breast Cancer, Anna M. Chiarelli, Jacques Simard, Nora Pashayan, Marie-Hélène Guertin, Michael Wolfson, Jodi M. Gatley, Christina Diong, Soo Jin Seung, Nicole Mittmann, Current Oncology, 2022, 10.3390/curroncol29110657
  • Variations of pre-prosomatostatin mRNA levels in the hypothalamic periventricular nucleus during the rat estrous cycle, , Mol Cell Neurosci, 1991
  • Recent advances in androgen receptor research : relative potencies of pure antiandrogens and implications for prostate cancer therapy, , New diagnostic and treatment modalities in prostate cancer : a comprehensive guide to current strategies in management, 1997
  • Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada, , J Pers Med, 2021, 10.3390/jpm11020095
  • Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?, , Fam Cancer, 2017, 10.1007/s10689-016-9920-6
  • Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations, , Hum Mutat, 2018, 10.1002/humu.23406
  • Codon 367 polymorphism of the human type I 3 beta-hydroxysteroid dehydrogenase/isomerase gene (HS5DB3), , Nucleic Acids Res, 1991, 10.1093/nar/19.21.6060
  • Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer, , Cancer Epidemiol Biomarkers Prev, 2017, 10.1158/1055-9965.Epi-16-0735
  • [Structure and expression of the genes encoding the enzymes for ovarian and peripheral steroidogenesis], , J Gynecol Obstet Biol Reprod (Paris), 1992
  • Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium, , Hum Mol Genet, 2014, 10.1093/hmg/ddu311
  • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer, , Gynecol Oncol, 2016, 10.1016/j.ygyno.2015.04.034
  • A new insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency, , Endocr Res, 2000, 10.3109/07435800009048597
  • No evidence of mutations in the genes for type I and type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) in nonclassical 3 beta HSD deficiency, , J Clin Endocrinol Metab, 1994, 10.1210/jcem.79.6.7989489
  • Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study, , Cancer Epidemiol Biomarkers Prev, 2007, 10.1158/1055-9965.Epi-06-0829
  • Multihormonal control of pre-pro-somatostatin mRNA levels in the periventricular nucleus of the male and female rat hypothalamus, , Neuroendocrinology, 1990, 10.1159/000125639
  • Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry, , Breast Cancer Res, 2016, 10.1186/s13058-016-0786-1
  • Androgens and breast cancer, , Cancer Detect Prev, 1992
  • Ovarian 3 beta-hydroxysteroid dehydrogenase and sulfated glycoprotein-2 gene expression are differentially regulated by the induction of ovulation, pseudopregnancy, and luteolysis in the immature rat, , Endocrinology, 1992, 10.1210/endo.130.4.1547735
  • A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium, , Hum Mol Genet, 2014, 10.1093/hmg/ddt581
  • Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers, , Br J Cancer, 2019, 10.1038/s41416-019-0492-8
  • Influence of the duration of androgen deprivation on the sensitivity of the rat ventral prostate to dehydroepiandrosterone and androstenedione, , Ann N Y Acad Sci, 1990
  • The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers, , Cancer Epidemiol Biomarkers Prev, 2017, 10.1158/1055-9965.Epi-16-0106
  • Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer, , NPJ Breast Cancer, 2020, 10.1038/s41523-020-00185-6
  • The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group, , Am J Hum Genet, 2000
  • Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study, , Br J Cancer, 2012, 10.1038/bjc.2012.160
  • Ontogenesis of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in the rat adrenal as revealed by immunocytochemistry and in situ hybridization, , Endocrinology, 1991, 10.1210/endo-129-5-2687
  • Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2., Domchek SM, Nathanson KL, Montagna M, Offit K, Rantala J, Borg A, Pejovic T, van Overeem Hansen T, Nielsen FC, Nikitina-Zake L, Janavicius R, James PA, Vellone VG, Gismondi V, Varesco L, Danesi R, Zampiga V, Dhawan M, Heli Nevanlinna, Miguel de la Hoya, Ana Vega, Susan Neuhausen, HEBON Investigators, Inge Søkilde Pedersen, Amanda Ewart Toland, Peter Hulick, Lazaro C, Wendy Chung, Manuel R. Teixeira, Claes KBM, Mai PL, Caligo MA, Soucy P, Bane A, Jacques Simard, Adalgeir Arason, Andrew Godwin, Anna Jakubowska, Jeffrey Weitzel, Hake CR, Daly MB, Sharma P, Irene L. Andrulis, Imyanitov EN, Hamann U, John EM, Hadjisavvas A, Nicola S Meagher, Southey MC, Susan Ramus, Denise G. O'Mahony, British journal of cancer, 2023, 10.1038/s41416-023-02263-5
  • Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?, , J Pers Med, 2021, 10.3390/jpm11090916
  • [From the gene to the clinic: prostate cancer death can now be an exception?], , Med Sci (Paris), 2003, 10.1051/medsci/20031910910
  • Third and fourth generation SERMs, , Selective estrogen receptor modulators: research and clinical applications, 2002
  • The Tumor Suppressor PALB2: Inside Out, , Trends Biochem Sci, 2019, 10.1016/j.tibs.2018.10.008
  • Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation, , Nat Commun, 2018, 10.1038/ncomms16193
  • Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk, , Hum Mol Genet, 2015, 10.1093/hmg/ddu431
  • Survey of primary care physicians' views about breast and ovarian cancer screening for true BRCA1/2 non-carriers, , J Community Genet, 2020, 10.1007/s12687-019-00438-3
  • Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line, , Endocrinology, 1989, 10.1210/endo-125-1-392
  • Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2, , Hum Mol Genet, 2015, 10.1093/hmg/ddv035
  • Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers, , Breast Cancer Res, 2020, 10.1186/s13058-020-1247-4
  • BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers, , J Natl Cancer Inst, 2016, 10.1093/jnci/djv315
  • Localization of the endogenous benzodiazepine ligand octadecaneuropeptide in the rat testis, , Endocrinology, 1990, 10.1210/endo-127-4-1986
  • Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study., Eliassen AH, Diana M Eccles, Dwek M, Thilo Dörk, Devilee P, Daly MB, Czene K, Cross SS, Cox A, Couch FJ, Conroy DM, Clarke CL, Chanock SJ, Chang-Claude J, Cessna MH, Castelao JE, Canzian F, Campa D, Camp NJ, Buys SS, Brüning T, Hermann Brenner, Bonanni B, Stig Bojesen, Bogdanova NV, Blomqvist C, Bermisheva M, Behrens S, Beckmann MW, Becher H, Beane Freeman LE, Auvinen P, Augustinsson A, Aronson KJ, Arndt V, Anton-Culver H, Andrulis IL, Ambrosone CB, Ahearn TU, Investigators A, Lush M, Dennis J, Wang Q, Bolla MK, Michailidou K, Giles GG, Terry Boyle, English DR, Richard Martin, Lewis SJ, Suzanne C. Dixon-Suen, British journal of sports medicine, 2022, 10.1136/bjsports-2021-105132
  • Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus, , PLoS One, 2016, 10.1371/journal.pone.0160316
  • Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers, , Hum Mol Genet, 2009, 10.1093/hmg/ddp372
  • Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans, , Hum Mol Genet, 2015, 10.1093/hmg/ddv203
  • Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells, , J Steroid Biochem Mol Biol, 1998, 10.1016/s0960-0760(98)00031-4
  • Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer, , J Med Genet, 2007, 10.1136/jmg.2006.044388
  • Localization of the catalytic subunit C gamma of the cAMP-dependent protein kinase gene (PRKACG) to human chromosome region 9q13, , Cytogenet Cell Genet, 1992, 10.1159/000133286
  • The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes, , Fam Cancer, 2016, 10.1007/s10689-015-9835-7
  • Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I), , J Pers Med, 2021, 10.3390/jpm11060511
  • Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency, , J Clin Endocrinol Metab, 1994, 10.1210/jcem.79.4.7962268
  • New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes, , J Clin Endocrinol Metab, 1999, 10.1210/jcem.84.12.6288
  • Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group, , J Clin Oncol, 2006, 10.1200/jco.2005.03.3126
  • A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study, , Cancers (Basel), 2021, 10.3390/cancers13112729
  • Androgènes, , Pharmacologie clinique: bases de la thérapeutique, 1988
  • Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency, , Mol Endocrinol, 1993, 10.1210/mend.7.5.8316254
  • ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry, , PLoS One, 2016, 10.1371/journal.pone.0156820
  • Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis, , Int J Epidemiol, 2019, 10.1093/ije/dyy201
  • The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations, , JNCI Cancer Spectr, 2018, 10.1093/jncics/pky078
  • Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities, , Adv Protein Chem, 2001, 10.1016/s0065-3233(01)56009-x
  • Occurrence of cytochrome P450c17 mRNA and dehydroepiandrosterone biosynthesis in the rat gastrointestinal tract, , Mol Cell Endocrinol, 1995, 10.1016/0303-7207(95)03553-j
  • The 3b-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3ß-HSD congenital deficiency, , Signal transduction in testicular cells: basic and clinical aspects, 1996
  • Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells, , J Steroid Biochem Mol Biol, 1994, 10.1016/0960-0760(94)90090-6
  • Expression of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) and 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) in adipose tissue, , Int J Obes, 1991
  • Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells, , Mol Endocrinol, 1989, 10.1210/mend-3-4-694
  • Shared heritability and functional enrichment across six solid cancers, , Nat Commun, 2019, 10.1038/s41467-018-08054-4
  • Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers, , PLoS One, 2016, 10.1371/journal.pone.0158801
  • Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers, , J Natl Cancer Inst, 2017, 10.1093/jnci/djw302
  • Isolation and sequence of the human glucocorticoid receptor gene promoter, , Steroid receptors in health and disease, 1988
  • Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency, , Semin Reprod Med, 2002, 10.1055/s-2002-35373
  • Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families, , BMC Med Genet, 2012, 10.1186/1471-2350-13-46
  • A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer, , Nat Genet, 2018, 10.1038/s41588-018-0132-x
  • Genetic linkage mapping of the dehydroepiandrosterone sulfotransferase (STD) gene on the chromosome 19q13.3 region, , Genomics, 1995, 10.1006/geno.1995.9935
  • Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study., Antonis Antoniou, Hall P, Easton DF, Schmidt MK, Simard J, Mavaddat N, Carvalho S, Dorling L, Dennis J, Wang J, Lush M, Leslie G, Andrew Lee, Czene K, mikael eriksson, Xin Yang, Journal of medical genetics, 2022, 10.1136/jmg-2022-108806
  • Localization of the human gene for the type I cyclic GMP-dependent protein kinase to chromosome 10, , Cytogenet Cell Genet, 1992, 10.1159/000133267
  • Prostate cancer susceptibility genes: lessons learned and challenges posed, , Endocr Relat Cancer, 2003, 10.1677/erc.0.0100225
  • Intracrinology and hormone-dependent cancers, , Epitheorese klinikes farmakologias kai farmakokinetikes = Review of clinical pharmacology and pharmacokinetics, 1997
  • Electron microscopic autoradiographic localization of prolactin mRNA in rat pituitary, , J Histochem Cytochem, 1989, 10.1177/37.5.2703695
  • Expression of liver-specific member of the 3 beta-hydroxysteroid dehydrogenase family, an isoform possessing an almost exclusive 3-ketosteroid reductase activity, , J Biol Chem, 1992
  • Self-reported mammography use following BRCA1/2 genetic testing may be overestimated, , Fam Cancer, 2012, 10.1007/s10689-011-9490-6
  • Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia, , Arterioscler Thromb Vasc Biol, 1998, 10.1161/01.atv.18.6.1007
  • BRCA2 germline mutations in male breast cancer cases and breast cancer families, , Nat Genet, 1996, 10.1038/ng0596-123
  • A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers, , Nat Commun, 2021, 10.1038/s41467-020-20496-3
  • Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines, , Endocrinology, 1999, 10.1210/endo.140.10.7038
  • Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers, , Nat Commun, 2021, 10.1038/s41467-021-23162-4
  • Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks, , Genet Med, 2021, 10.1038/s41436-021-01258-y
  • Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer, , Nat Genet, 2017, 10.1038/ng.3785
  • Les enjeux éthiques de l'identification d'une susceptibilité génétique au cancer du sein dans un contexte de recherche clinique intégrée, , Les pratiques de recherche biomédicale visitées par la bioéthique, 2003
  • Analysis of multivariate failure times in the presence of selection bias with application to breast cancer, , J R Stat Soc Ser C Appl Stat, 2015
  • Pure antagonistic effect of a new steroidal antiestrogen in rat anterior pituitary cells in culture and in mouse uterus, , Ann N Y Acad Sci, 1990
  • Synthèse périphérique des androgènes chez l'homme. Génétique moléculaire du système et sa prise en compte dans le traitement du cancer de la prostate, , Med Sci (Paris), 1990
  • Characterization of rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase cDNAs and differential tissue-specific expression of the corresponding mRNAs in steroidogenic and peripheral tissues, , J Biol Chem, 1991
  • Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model, , Genet Med, 2016, 10.1038/gim.2016.31
  • Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer, , J Steroid Biochem Mol Biol, 2009, 10.1016/j.jsbmb.2009.05.005
  • Health professionals' perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease, , Public Health Rev, 2019, 10.1186/s40985-019-0111-5
  • Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells, , Mol Cell Endocrinol, 1996, 10.1016/0303-7207(96)03843-9
  • Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells, , Endocrinology, 1992, 10.1210/endo.130.3.1537279
  • Structure and control of expression of the 3b-HSD and 17b-HSD genes in classical steroidogenic and peripheral intracrine tissues, , Molecular Basis of Reproductive Endocrinology, 1993
  • Authors' response: Associations of obesity and circulating insulin and glucose with breast cancer risk, , Int J Epidemiol, 2019, 10.1093/ije/dyz015
  • Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade, , Hum Mol Genet, 2014, 10.1093/hmg/ddu300
  • Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families, , BMC Cancer, 2006, 10.1186/1471-2407-6-230
  • Proceedings of the Xth International Congress on Hormonal Steroids. Quebec City, Canada 17-21 June 1998, , 1999
  • Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk, , PLoS Genet, 2013, 10.1371/journal.pgen.1003173
  • Polygenic risk scores for prediction of breast cancer risk in Asian populations., Kweon SS, Yamaji T, Iwasaki M, Allison Kurian, John EM, Chan TL, Kwong A, Ito H, Matsuo K, Tseng CC, Wu AH, Lophatananon A, Muir KR, Park B, Wu PE, CHEN-YANG SHEN, Kim SW, Park SK, BioBank Japan Project, Shinichi Namba, Okada Y, Kubo M, Lee HB, Han W, Choi JY, Kang D, Zheng Y, Gao YT, Lim SH, Tan EY, Tan SM, Tan BKT, Tan VKM, Rahmat K, Hassan T, Wijaya EA, Long J, Kyriaki Michailidou, Wang Q, Bolla MK, Mavaddat N, Lee SH, Jee YH, Lin K, Millwood IY, Ho PJ, Li J, Shu X, Dennis J, Tai MC, Ho WK, Genetics in medicine : official journal of the American College of Medical Genetics, 2021, 10.1016/j.gim.2021.11.008
  • Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients, , J Clin Endocrinol Metab, 1996, 10.1210/jcem.81.1.8550762
  • Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk, , Int J Epidemiol, 2019, 10.1093/ije/dyz047
  • Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium, , Int J Cancer, 2017, 10.1002/ijc.30859
  • Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model., Douglas Easton, Antonis Antoniou, Jacques Simard, Dr. Judith Balmaña, Lidia Feliubadaló, Monica Pardo Muñoz, Wendy Chung, Cong Liu, Stig Bojesen, Anna Chiarelli, Tong Zhang, Gregory S Downs, Tracy Stockley, Rita Schmutzler, Eric Hahnen, Donglei Hu, Kate Downes, Marc Tischkowitz, Joe Dennis, Michael Lush, Alex Cunningham, Andrew Lee, Tim, Lorenzo Ficorella, Nasim Mavaddat, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2023, 10.1158/1055-9965.epi-22-0756
  • A focus group study on breast cancer risk presentation: one format does not fit all, , Eur J Hum Genet, 2013, 10.1038/ejhg.2012.248
  • Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers, , J Clin Oncol, 2013, 10.1200/jco.2012.47.8313
  • Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study, , JNCI Cancer Spectr, 2018, 10.1093/jncics/pky023
  • Steroid modulation of LHRH action, , Steroid modulation of neuroendocrine function; Sterols, steroids, and bone metabolism: proceedings of the XI Meeting of the International Study Group for Steroid Hormones, Rome, November 30-December 2, 1983, 1984
  • Medical genetic counseling for breast cancer in primary care: a synthesis of major determinants of physicians' practices in primary care settings, , Public Health Genomics, 2014, 10.1159/000362358
  • Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study, , Genet Med, 2012, 10.1038/gim.0b013e3182310a7f
  • Legal liability and the uncertain nature of risk prediction: the case of breast cancer risk prediction models, , Public Health Genomics, 2012, 10.1159/000342138
  • The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer, , NPJ Breast Cancer, 2019, 10.1038/s41523-019-0127-5
  • Relative potency of bicalutamide (Casodex) and flutamide (Eulexin) (Letter to the Editor : reply to Kolvenbag GJ et al; 50:913-919, 1997), , Urology, 1999
  • Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core, , Hum Mutat, 1996, 10.1002/humu.1380080102
  • Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer, , Genet Test Mol Biomarkers, 2010, 10.1089/gtmb.2010.0027
  • Evidence of a founder effect for the protein C gene 3363 inserted C mutation in thrombophilic pedigrees of French origin, , Thromb Haemost, 2001
  • The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology, , Steroids, 1997, 10.1016/s0039-128x(96)00174-2
  • PALB2 Variants: Protein Domains and Cancer Susceptibility, , Trends Cancer, 2021, 10.1016/j.trecan.2020.10.002
  • Transcriptome-wide association study of breast cancer risk by estrogen-receptor status, , Genet Epidemiol, 2020, 10.1002/gepi.22288
  • European polygenic risk score for prediction of breast cancer shows similar performance in Asian women, , Nat Commun, 2020, 10.1038/s41467-020-17680-w
  • Prostate cancer suceptibility genes, , Prostate Cancer: Understanding the Pathophysiology and Re-Designing A Therapeutic Approach, 2004
  • Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization, , J Natl Cancer Inst, 2015, 10.1093/jnci/djv219
  • An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression, , Hum Mol Genet, 2016, 10.1093/hmg/ddw223
  • Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer, , Nat Commun, 2016, 10.1038/ncomms11375
  • A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population, , Nat Genet, 2010, 10.1038/ng.669
  • Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells, , Mol Cell Endocrinol, 1990, 10.1016/0303-7207(90)90130-z
  • Molecular biology and genetics of the 3 beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family, , J Endocrinol, 1996
  • Somatostatin prevents the desensitizing action of growth hormone-releasing factor on growth hormone release, , Peptides, 1987, 10.1016/0196-9781(87)90090-8
  • Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer, , Cancer Res, 2018, 10.1158/0008-5472.Can-18-1018
  • Rapid modulation of ovarian 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat, , Mol Cell Endocrinol, 1994, 10.1016/0303-7207(94)90147-3
  • Characterization of two mRNA species encoding human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17, , J Steroid Biochem, 1989, 10.1016/0022-4731(89)90082-4
  • Localization of 3 beta-hydroxysteroid dehydrogenase in rat brain as studied by in situ hybridization, , Mol Cell Neurosci, 1994, 10.1006/mcne.1994.1014
  • Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer, , J Hum Genet, 2008, 10.1007/s10038-008-0276-0
  • Adrenal C19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs, , J Steroid Biochem, 1987, 10.1016/0022-4731(87)90005-7
  • Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation, , Am J Hum Genet, 2016, 10.1016/j.ajhg.2016.07.017
  • Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor, , Mol Endocrinol, 2002, 10.1210/mend.16.7.0875
  • Detection of frequent BglII polymorphism by polymerase chain reaction and TaqI restriction fragment length polymorphism for 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase at the human HSD beta 3 locus (1p11-p13), , Hum Genet, 1991, 10.1007/bf00201743
  • Cloning of the human androgen receptor cDNA, , Hormones and cancer 3: proceedings of the Third International Congress on Hormones and Cancer, 1988
  • Physicians, genetics and life insurance, , Cmaj, 2004, 10.1503/cmaj.1040127
  • Males With 17[beta]-Hydroxysteroid Dehydrogenase Deficiency, , Endocrinologist, 2003
  • Molecular cloning, cDNA structure and predicted amino acid sequence of bovine 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase, , FEBS Lett, 1989, 10.1016/0014-5793(89)81516-9
  • p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6, , Nucleic Acids Res, 1999, 10.1093/nar/27.13.2722
  • Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. , Evans DG, Engel C, Eliassen AH, Ekici AB, Diana M Eccles, Dwek M, Dossus L, Thilo Dörk, Devilee P, Daly MB, Czene K, Couch FJ, Cornelissen S, CTS Consortium, Colonna SV, NBCS Collaborators, Chung WK, Choi JY, Chanock SJ, Chang-Claude J, Chan TL, Castelao JE, Buys SS, Brucker SY, Hermann Brenner, Bonanni B, Stig Bojesen, Bogdanova NV, Blomqvist C, Bermisheva M, Benitez J, Behrens S, Beckmann MW, Freeman LEB, Baert T, Augustinsson A, Aronson KJ, Arndt V, Antonenkova NN, Anton-Culver H, Andrulis IL, Ahearn TU, Abu-Ful Z, Lush M, Dennis J, Wang Q, Bolla MK, Michailidou K, Valkovskaya M, Alvina Lai, Mueller SH, Genome medicine, 2023, 10.1186/s13073-022-01152-5
  • Mapping of the HSD17B2 gene encoding type II 17 beta-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1-q24.2, , Genomics, 1995, 10.1016/0888-7543(95)80017-g
  • EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium, , Current knowledge in reproductive medicine: proceedings of the 10th World Congress on Human Reproduction, Salvador, Brazil, 4-8th May, 1999, 2000
  • 3b-hydroxysteroid dehydrogenase D5- D4-isomerase deficiency, , Genetics of steroid biosynthesis and function, 2002
  • Adrenal steroids exert potent estrogen action in both normal and cancer tissue, , Hormonal manipulation of cancer: peptides, growth factors, and new (anti)steroidal agents, 1987
  • Assignment of the gene encoding the catalytic subunit C beta of cAMP-dependent protein kinase to the p36 band on chromosome 1, , Hum Genet, 1992, 10.1007/bf02265292
  • Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), , JAMA Oncol, 2020, 10.1001/jamaoncol.2020.2134
  • Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers, , Breast Cancer Res, 2020, 10.1186/s13058-020-01259-w
  • Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women, , Breast Cancer Res, 2016, 10.1186/s13058-016-0768-3
  • The association between weight at birth and breast cancer risk revisited using Mendelian randomisation, , Eur J Epidemiol, 2019, 10.1007/s10654-019-00485-7
  • Return of research results: general principles and international perspectives, , J Law Med Ethics, 2011, 10.1111/j.1748-720X.2011.00625.x
  • The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers, , Br J Cancer, 2009, 10.1038/sj.bjc.6605279
  • Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21, , Hum Mol Genet, 1993, 10.1093/hmg/2.4.479
  • Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads, , Mol Endocrinol, 1991, 10.1210/mend-5-8-1147
  • Characterization of the guinea pig 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4-isomerase expressed in the adrenal gland and gonads, , J Steroid Biochem Mol Biol, 2005, 10.1016/j.jsbmb.2005.05.011
  • CYP17 and breast cancer: no overall effect, but what about interactions?, , Breast Cancer Res, 2005, 10.1186/bcr1320
  • Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers, , Am J Hum Genet, 2013, 10.1016/j.ajhg.2013.01.002
  • Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group, , J Clin Oncol, 2007, 10.1200/jco.2007.11.1179
  • Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures, , Cancer Res, 2015, 10.1158/0008-5472.Can-14-2012
  • BRCA1 mutations in Ashkenazi Jewish women, , Am J Hum Genet, 1995
  • BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations, , Cancer Epidemiol Biomarkers Prev, 2003
  • Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent, , PLoS Med, 2016, 10.1371/journal.pmed.1002105
  • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers, , Jama, 2017, 10.1001/jama.2017.7112
  • Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease, , J Mol Endocrinol, 2000, 10.1677/jme.0.0250001
  • The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers, , Cancer Epidemiol Biomarkers Prev, 2006, 10.1158/1055-9965.Epi-05-0709
  • Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores, , J Natl Cancer Inst, 2021, 10.1093/jnci/djab147
  • Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers, , Breast Cancer Res Treat, 2010, 10.1007/s10549-009-0601-0
  • Perspective: prostate cancer susceptibility genes, , Endocrinology, 2002, 10.1210/endo.143.6.8890
  • Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1, , Am J Hum Genet, 2015, 10.1016/j.ajhg.2014.11.009
  • An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers, , Breast Cancer Res, 2015, 10.1186/s13058-015-0567-2
  • Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer, , Eur Urol, 1993, 10.1159/000474399
  • Life insurance: genomic stratification and risk classification, , Eur J Hum Genet, 2014, 10.1038/ejhg.2013.228
  • Functional characterization of 84 PALB2 variants of uncertain significance, , Genet Med, 2020, 10.1038/s41436-019-0682-z
  • Atrial natriuretic factor does not affect basal, forskolin- and CRF-stimulated adenylate cyclase activity, cAMP formation or ACTH secretion, but does stimulate cGMP synthesis in anterior pituitary, , Mol Cell Endocrinol, 1986, 10.1016/0303-7207(86)90054-7
  • SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival, , Oncotarget, 2015, 10.18632/oncotarget.4991
  • Genomic organization and expression of the mouse Brca2 gene, , Mamm Genome, 2002, 10.1007/s00335-002-2300-6
  • A new alternative splice variant of BRCA1 containing an additional in-frame exon, , Biochim Biophys Acta, 2005, 10.1016/j.bbaexp.2005.08.011
  • Rare germline copy number variants (CNVs) and breast cancer risk., Haiman CA, Hahnen E, Pascal Guenel, González-Neira A, Graham Giles, Montserrat Garcia-Closas, Gago-Dominguez M, Marike Gabrielson, Lin Fritschi, Flyger H, Fletcher O, Jonine Figueroa, Fasching PA, Gareth Evans, mikael eriksson, Eliassen AH, Laure Dossus, Thilo Dörk, Devilee P, Czene K, Cross SS, Angela Cox, Couch FJ, CTS Consortium, Collée JM, NBCS Collaborators, Clarke CL, Chenevix-Trench G, Chang-Claude J, Jose E Castelao, Hermann Brenner, Stig Bojesen, Bogdanova NV, Bermisheva M, Benitez J, Sabine Behrens, Beckmann MW, Freeman LEB, Kristan Aronson, Volker Arndt, Antonenkova NN, Anton-Culver H, Irene L. Andrulis, Ahearn TU, Qin Wang, Bolla MK, Dorling L, Kyriaki Michailidou, Logan Walker, Jonathan Tyrer, Joe Dennis, Communications biology, 2022, 10.1038/s42003-021-02990-6
  • Functional analysis of promoter variants in KU70 and their role in cancer susceptibility, , Genes Chromosomes Cancer, 2012, 10.1002/gcc.21983
  • GATA factors and the nuclear receptors, steroidogenic factor 1/liver receptor homolog 1, are key mutual partners in the regulation of the human 3beta-hydroxysteroid dehydrogenase type 2 promoter, , Mol Endocrinol, 2005, 10.1210/me.2004-0257
  • Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy, , J Obstet Gynaecol Can, 2004, 10.1016/s1701-2163(16)30432-7
  • Le déficit en 3beta-hydroxystéroide déshydrogénase delta5-delta4 isomérase : hétérogénéité des formes cliniques et apport de la biologie, , Rev Fr Endocrinol Clin, 1994
  • Nonsalt-losing male pseudohermaphroditism due to the novel homozygous N100S mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene, , J Clin Endocrinol Metab, 1995, 10.1210/jcem.80.7.7608265
  • A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics, , Am J Hum Genet, 2005, 10.1086/432377
  • Structure-function relationships of multiple rat members of the 3b-hydroxysteroid dehydrogenase family (Chapter 14), , Molecular Basis of Reproductive Endocrinology, 1993
  • A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation, , EMBO Mol Med, 2018, 10.15252/emmm.201809172
  • Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk, , Eur J Hum Genet, 2013, 10.1038/ejhg.2012.286
  • A genome-wide gene-based gene-environment interaction study of breast cancer in more than 90,000 women., Figueroa J, Montserrat Garcia-Closas, Eliassen H, Tamimi R, Peng C, Love MI, Troester MA, Long J, Zheng W, Goldberg MS, Simard J, Winham S, Scott C, Maskarinec G, Haiman CA, Giles GG, Becher H, Jung A, Kosma VM, Mannermaa A, Behrens S, Lo WY, Hoppe R, Arndt V, Brenner H, Kaaks R, Canzian F, Hodge JM, Teras LR, Truong T, Guénel P, Aronson K, Murphy RA, Shibli R, Rennert G, Stone J, Beane Freeman LE, Koutros S, Southey MC, Hopper JL, Pharoah PDP, Kyriaki Michailidou, Wang Q, Lush M, Dunning AM, Dennis J, Bolla MK, Su YR, Middha Kapoor P, Chen H, Wang X, Cancer research communications, 2022, 10.1158/2767-9764.crc-21-0119
  • Women’s perceptions of PERSPECTIVE: a breast cancer risk stratification e-platform, Carmen Loiselle, Jacques Simard, Michel Dorval, Bartha Knoppers, Rosalind Garland, Emmanuelle Lévesque, Saima Ahmed, Hereditary Cancer in Clinical Practice, 2022, 10.1186/s13053-022-00214-4
  • Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions., Matthew H. Law, Kanetsky PA, Mark Iles, Goldstein AM, Demenais F, Bishop DT, International Lung Cancer Consortium (ILCCO), Tardon A, Landi MT, Amos CI, Aldrich MC, Mckay J, Mattias Johansson, Christiani DC, Paul Brennan, Wrensch M, Melin B, Jenkins RB, Richard Houlston, Bondy ML, Barnholtz-Sloan J, Johannes Schumacher, Stuart MacGregor, Jankowski J, Gockel I, Puya Gharahkhani, Fitzgerald R, Endometrial Cancer Association Consortium (ECAC), Tomlinson I, Spurdle AB, O'Mara TA, De Vivo I, Colorectal Transdisciplinary Study (CORECT), Colon Cancer Family Registry Study (CCFR), Genetics And Epidemiology Of Colorectal Cancer Consortium (GECCO), Kenneth Offit, Victor Moreno, Loic Le Marchand, Gunter MJ, Stephen B. Gruber, Gallinger S, Breast Cancer Association Consortium (BCAC), Bammler T, Mancuso N, Hongjie Chen, Constance Turman, Harrison T, Macdonald J, Huo S, Majumdar A, Feng H, Wang L, Sara Lindstrom, Journal of the National Cancer Institute, 2023, 10.1093/jnci/djad043
  • Science behind total androgen blockade: from gene to combination therapy, , Clin Invest Med, 1993
  • Structure of human type II 5 alpha-reductase gene, , Endocrinology, 1992, 10.1210/endo.131.3.1505484
  • VEXOR: an integrative environment for prioritization of functional variants in fine-mapping analysis, , Bioinformatics, 2017, 10.1093/bioinformatics/btw826
  • Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses, , Nat Genet, 2020, 10.1038/s41588-020-0609-2
  • Relatives potencies of flutamide and casodex : preclinical studies, , Endocr Relat Cancer, 1996
  • Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement, , Nat Rev Clin Oncol, 2020, 10.1038/s41571-020-0412-0
  • Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec, , Eur J Hum Genet, 2011, 10.1038/ejhg.2010.227
  • Genetic discrimination and life insurance: a systematic review of the evidence, , BMC Med, 2013, 10.1186/1741-7015-11-25
  • Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers, , Cancer Epidemiol Biomarkers Prev, 2010, 10.1158/1055-9965.Epi-10-0517
  • Role of DHEA transformation into androgens and estrogens in peripheral intracrine tissues, , DHEA: a comprehensive review, 1999
  • Contralateral breast cancer risk in irradiated breast cancer patients with a germline-BRCA1/2 pathogenic variant, Christoph Engel, Kerstin Rhiem, Marc Tischkowitz, Miguel de la Hoya, Marjanka K. Schmidt, Carole Brewer, Jacques Simard, Maartje J. Hooning, 2023, 10.1093/jnci/djad116
  • Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16' alpha-chloro-3',17 beta-dihydroxy-estra-1',3',5'-(10')triene-7' alpha-yl] undecanamide in human breast cancer ZR-75-1 cells, , Cancer Res, 1991
  • History of LHRH agonist and combination therapy in prostate cancer, , Endocr Relat Cancer, 1996
  • Androgenic 17 beta-hydroxysteroid dehydrogenase activity of expressed rat type I 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase, , Endocrinology, 1992, 10.1210/endo.130.1.1309351
  • Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites, , J Med Genet, 1996, 10.1136/jmg.33.10.814
  • 17alpha-hydroxylase/17,20-Lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sister, , J Pediatr Endocrinol Metab, 2005, 10.1515/jpem.2005.18.4.403
  • RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies, , Am J Hum Genet, 2007, 10.1086/522611
  • EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium, , J Steroid Biochem Mol Biol, 1999, 10.1016/s0960-0760(99)00065-5
  • Cloning, expression and regulation of tissue-specific expression of 3b-hydroxysteroid dehydrogenase/D5-D4 isomerase, , Cellular and molecular biology of the adrenal cortex: proceedings of the 5th International Symposium on Cellular and Molecular Biology of the Adrenal Cortex held in Avignon (France) August 27-29, 1992, 1992
  • Localization of BRCA1 gene expression in adult cynomolgus monkey tissues, , J Histochem Cytochem, 1997, 10.1177/002215549704500901
  • DHEA replacement therapy as a source of androgens and estrogens at menopause, , Advances in gynecological endocrinology: the proceedings of the plenary sessions of the 8th World Congress of Gynecological Endocrinology, Florence, Italy, December 2000, 2002
  • Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13, , Genomics, 1996, 10.1006/geno.1996.0428
  • Regulation of pro-gonadotropin-releasing hormone gene expression by sex steroids in the brain of male and female rats, , Mol Endocrinol, 1989, 10.1210/mend-3-11-1748
  • Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects, , NPJ Breast Cancer, 2021, 10.1038/s41523-021-00255-3
  • Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada), , BMJ Open, 2018, 10.1136/bmjopen-2017-016662
  • Canadian Healthcare Professionals’ Views and Attitudes toward Risk-Stratified Breast Cancer Screening, Hermann Nabi, Jacques Simard, Anna Maria Chiarelli, Bartha Knoppers, Yann Joly, Kristina Maria Blackmore, Meghan J. Walker, Jennifer Brooks, Laurence Lambert-côté, Annie Turgeon, Laurence Eloy, Jocelyne Chiquette, Nora Pashayan, Michel Dorval, Cynthia Mbuya-Bienge, Jean-Martin Côté, Julie Lapointe, Journal of Personalized Medicine, 2023, 10.3390/jpm13071027
  • Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21, , Oncotarget, 2016, 10.18632/oncotarget.12818
  • Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants, , Nat Commun, 2020, 10.1038/s41467-020-15046-w
  • Localization of endogenous benzodiazepine ligand octadecaneuropeptide (ODN) and peripheral benzodiazepine receptors in the rat prostate, , Molecular Andrology, 1991
  • Synthesis and antiestrogenic activity of diaryl thioether derivatives, , J Med Chem, 1994, 10.1021/jm00034a009
  • Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2, , Biochim Biophys Acta, 2004, 10.1016/j.bbaexp.2004.07.001
  • Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?, , Cancer Res, 2004, 10.1158/0008-5472.can-03-2678
  • Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer, , J Steroid Biochem, 1989, 10.1016/0022-4731(89)90115-5
  • Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone, , Endocr Rev, 2003, 10.1210/er.2001-0031
  • Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families, , J Hum Genet, 2008, 10.1007/s10038-008-0285-z
  • Crucial role of cytokines in sex steroid formation in normal and tumoral tissues, , Mol Cell Endocrinol, 2001, 10.1016/s0303-7207(00)00387-7
  • The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant, , Genet Med, 2021, 10.1038/s41436-021-01198-7
  • Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer, , HGG Adv, 2021, 10.1016/j.xhgg.2021.100042
  • Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives, , Healthc Policy, 2019, 10.12927/hcpol.2019.26072
  • Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers, , Hum Mol Genet, 2011, 10.1093/hmg/ddr388
  • Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women, , N Engl J Med, 2021, 10.1056/NEJMoa1913948
  • Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair, , Nat Genet, 2015, 10.1038/ng.3412
  • Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers, , Cancer Epidemiol Biomarkers Prev, 2005
  • Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs), , Sci Rep, 2016, 10.1038/srep32512
  • Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues, , J Steroid Biochem Mol Biol, 1992, 10.1016/0960-0760(92)90390-5
  • Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population, , Int J Gynecol Cancer, 2012, 10.1097/IGC.0b013e318257b936
  • HRT use among women tested for BRCA1/2 mutations following publication of the women's health initiative study results, , J Obstet Gynaecol Can, 2005, 10.1016/s1701-2163(16)30455-8
  • Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers, , Can Assoc Radiol J, 2016, 10.1016/j.carj.2015.12.003
  • DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers, , PLoS Genet, 2014, 10.1371/journal.pgen.1004256
  • Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP1A1 gene and D15S204 in the chromosome 15q22.33-q23 region, , Pharmacogenetics, 1998, 10.1097/00008571-199802000-00007
  • Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians, , Hum Mutat, 1998, 10.1002/humu.1380110173
  • SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation, , Genet Epidemiol, 2015, 10.1002/gepi.21914
  • Molecular biology of the intracrine steroidogenic enzymes in the human prostate, , Sex hormones and antihormones in endocrine dependent pathology: basic and clinical aspects: proceedings of an international symposium, Milano, 10-14 April 1994, 1994
  • Regulation of 3-ketosteroid reductase messenger ribonucleic acid levels and 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase activity in rat liver by sex steroids and pituitary hormones, , Endocrinology, 1992, 10.1210/endo.131.6.1446638
  • RAD51B in Familial Breast Cancer, , PLoS One, 2016, 10.1371/journal.pone.0153788
  • Full oestrogenic activity of C19-delta 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs, , Mol Cell Endocrinol, 1988, 10.1016/0303-7207(88)90138-4
  • Structure and tissue-specific expression of 3 beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues, , J Steroid Biochem Mol Biol, 1992, 10.1016/0960-0760(92)90368-s
  • Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer, , Endocrinology, 1990, 10.1210/endo-126-6-3223
  • DHEA and sex steroids : intracrinology in target tissues (Reprinted from Journal of endocrinology, vol. 150, supplement, September 1996), , 1996
  • Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence., Antonis Antoniou, Easton DF, Paul Pharoah, Mooij TM, Rookus M, De Pauw A, Mouret-Fourme E, Jürgens H, Vesna Zadnik, Peter Devilee, Schmidt MK, Simard J, Usher-Smith J, Roberts J, Tischkowitz M, Walter FM, Archer S, Lorenzo Ficorella, Carver T, Cunningham A, Mavaddat N, Andrew Lee, Journal of medical genetics, 2022, 10.1136/jmedgenet-2022-108471
  • Dinucleotide repeat polymorphisms in the HSD3B2 gene, , Hum Mol Genet, 1994, 10.1093/hmg/3.2.384
  • ["Intracrinology". Autonomy and freedom of peripheral tissues], , Ann Endocrinol (Paris), 1995
  • Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary gland, , Endocrinology, 1989, 10.1210/endo-125-4-1821
  • A Systematic Review and Critical Assessment of Breast Cancer Risk Prediction Tools Incorporating a Polygenic Risk Score for the General Population, Hermann Nabi, Jacques Simard, Julie Lapointe, Cornelia D. Kazemali, Nora Pashayan, Cynthia Mbuya-Bienge, Cancers, 2023, 10.3390/cancers15225380
  • Enhanced urinary prostaglandin E2 in postobstructive diuresis in humans, , Prostaglandins Med, 1980, 10.1016/0161-4630(80)90087-7
  • Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells, , J Biol Chem, 1990
  • Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution, , J Enzyme Inhib Med Chem, 2005, 10.1080/14756360500043448
  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer, , Nat Genet, 2013, 10.1038/ng.2566
  • Open science precision medicine in Canada: Points to consider, , Facets (Ott), 2019
  • BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families, , Breast Cancer Res, 2006, 10.1186/bcr1365
  • A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening, , Jama, 1995
  • Molecular cloning, upstream sequence and promoter studies of the human gene for the regulatory subunit RII alpha of cAMP-dependent protein kinase, , Biochim Biophys Acta, 1997, 10.1016/s0167-4781(96)00152-2
  • Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS), , J Natl Cancer Inst, 2006, 10.1093/jnci/djj132
  • FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium, , Br J Cancer, 2014, 10.1038/bjc.2013.769
  • Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers, , Am J Hum Genet, 2008, 10.1016/j.ajhg.2008.02.008
  • Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction, , Biostatistics, 2020, 10.1093/biostatistics/kxy075
  • The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers, , Breast Cancer Res Treat, 2011, 10.1007/s10549-010-1123-5
  • Cancer : What are the role and sources of steroid hormones and the possible role of adipose tissue?, , Progress in obesity research, 1996
  • Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer, , J Steroid Biochem Mol Biol, 2008, 10.1016/j.jsbmb.2007.10.004
  • Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer, , J Hum Genet, 2007, 10.1007/s10038-007-0203-9
  • Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia, , J Med Genet, 2018, 10.1136/jmedgenet-2017-104947
  • A Mendelian randomization analysis of circulating lipid traits and breast cancer risk, , Int J Epidemiol, 2020, 10.1093/ije/dyz242
  • Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers., Fostira F, Lidia Feliubadaló, Faust U, Gareth Evans, Christoph Engel, Hans Ehrencrona, Douglas Easton, Eason J, Donaldson A, Domchek SM, Ding YC, Diez O, Dhawan M, Delnatte C, Robin de Putter, Miguel de la Hoya, Davidson R, Sita Dandiker, Daly MB, Couch FJ, Cosgrove C, Cook J, Collonge-Rame MA, EMBRACE Collaborators, GEMO Study Collaborators, Kathleen Claes, Wendy Chung, Ian Campbell, Caligo MA, Buys SS, Joan Brunet, Bradbury AR, Borde J, Boonen SE, Marinus Blok, Berger L, Belhadj S, Barkardottir RB, Balmaña J, Jacopo Azzollini, Arun BK, Irene L. Andrulis, Aittomäki K, Peter Mace, Robinson BA, Daniel Barnes, Wiggins GAR, Joe Dennis, Marquart L, John F Pearson, Hakkaart C, Communications biology, 2022, 10.1038/s42003-022-03978-6
  • Opposite effects of prolactin and corticosterone on the expression and activity of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in rat skin, , J Invest Dermatol, 1994, 10.1111/1523-1747.ep12389663
  • Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13, , Mol Endocrinol, 1999, 10.1210/mend.13.1.0221
  • The emergence of an ethical duty to disclose genetic research results: international perspectives, , Eur J Hum Genet, 2006, 10.1038/sj.ejhg.5201690
  • Modulation by sex steroids and [D-Trp6, Des-Gly-NH2(10)]luteinizing hormone (LH)-releasing hormone ethylamide of alpha-subunit and LH beta messenger ribonucleic acid levels in the rat anterior pituitary gland, , Mol Endocrinol, 1988, 10.1210/mend-2-9-775
  • Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5'-termini in human placenta, , Mol Endocrinol, 1989, 10.1210/mend-3-8-1301
  • PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1, , Oncotarget, 2017, 10.18632/oncotarget.21800
  • Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues, , Mol Cell Endocrinol, 1986, 10.1016/0303-7207(86)90132-2
  • Genome-wide association study of germline variants and breast cancer-specific mortality, , Br J Cancer, 2019, 10.1038/s41416-019-0393-x
  • Glucocorticoid regulation of proopiomelanocortin mRNA levels in rat arcuate nucleus, , Mol Cell Neurosci, 1990
  • COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration, , Breast Cancer Res, 2013, 10.1186/bcr3434
  • Support groups for people carrying a BRCA mutation, , Cmaj, 2001
  • 17b-hydroxysteroid dehydrogenase and 5a-reductase eficiencies, , Genetics of steroid biosynthesis and function, 2002
  • Effects of sex steroids on regulation of the levels of C1 peptide of rat prostatic steroid-binding protein mRNA evaluated by in-situ hybridization, , J Mol Endocrinol, 1988, 10.1677/jme.0.0010213
  • Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy, , Cancer, 1993, 10.1002/1097-0142(19930201)71:3+<1059::aid-cncr2820711426>3.0.co;2-6
  • Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer, , Jama, 2015, 10.1001/jama.2014.5985
  • Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians, , Hum Mol Genet, 1994, 10.1093/hmg/3.9.1689
  • Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics, , Hum Genet, 2006, 10.1007/s00439-006-0219-9
  • Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273 delta AA in type II 3 beta-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin, , Hum Mol Genet, 1994, 10.1093/hmg/3.2.327
  • Polygenic risk modeling for prediction of epithelial ovarian cancer risk, Diana M. Eccles, Eleanor Davies, Daniel Barrowdale, Rita K. Schmutzler, Christoph Engel, Noura Mebirouk, Fabienne Lesueur, Sarah Colonna, Kathleen Claes, Wendy K. Chung, Yoke-Eng Chiew, Kexin Chen, Stephen Chanock, Jenny Chang-Claude, Hayley Cassingham, Rikki Cannioto, Ian Campbell, Maria A. Caligo, Hui Cai, Saundra S. Buys, Ralf Butzow, Agnieszka Budzilowska, James D. Brenton, Ake Borg, Bernardo Bonanni, Natalia V. Bogdanova, Amanda Black, Line Bjorge, Marcus Q. Bernardini, Marina Bermisheva, Javier Benitez, Alicia Beeghly-Fadiel, Matthias W. Beckmann, Daniel Barrowdale, Rosa B. Barkardottir, Elisa V. Bandera, Judith Balmaña, Annelie Augustinsson, Banu K. Arun, Gerasimos Aravantinos, Natalia N. Antonenkova, Hoda Anton-Culver, Irene L. Andrulis, Simona Agata, Muriel A. Adank, Katja K. H. Aben, Xin Yang, Michelle R. Jones, Daniel Barnes, Jonathan Tyrer, Eileen O. Dareng, European Journal of Human Genetics, 2022, 10.1038/s41431-021-00987-7
  • A network analysis to identify mediators of germline-driven differences in breast cancer prognosis, , Nat Commun, 2020, 10.1038/s41467-019-14100-6
  • Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture, , DNA, 1986, 10.1089/dna.1986.5.263
  • Functional characterization of the novel L108W and P186L mutations detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia, , Hum Mol Genet, 1994, 10.1093/hmg/3.9.1639
  • Influence of the family cluster effect on psychosocial variables in families undergoing BRCA1/2 genetic testing for cancer susceptibility, , Psychooncology, 2012, 10.1002/pon.1936
  • Structure of two in tandem human 17 beta-hydroxysteroid dehydrogenase genes, , Mol Endocrinol, 1990, 10.1210/mend-4-2-268
  • Hérédité et cancer du sein : les gènes de susceptibilité BRCA1 et BRCA2, , Actualité Médicale, 1999
  • Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry, Jacques Simard, Eric Hahnen, MK Schmidt, Douglas F. Easton, Rita K. Schmutzler, Irene L. Andrulis, David E. Goldgar, Alfons Meindl, Gary Bader, Sean Tavtigian, Peter Devilee, GHS Study Group, Genome of the Netherlands Project, Bernhard H.F. Weber, Shan Wang-Gohrke, Qin Wang, Quinten Waisfisz, Michael Wagner, Alexander E. Volk, Rob B. van der Luijt, Lizet van der Kolk, Christi J. van Asperen, Holger Thiele, Christian Sutter, Tim M. Strom, Antje Stäbler, Martin Scherer, Mitul Shah, Gunnar Schmidt, Steffi Riedel-Heller, Juliane Ramser, Alfredo Ramirez, Paul D. P. Pharoah, Annette Peters, Claus-Eric Ott, Peter Nürnberg, Dieter Niederacher, John Martens, Wolfgang Maier, Craig Luccarini, Renske Keeman, Renske Keeman, Silke Kaulfuß, M. Arfan Ikram, Judit Horváth, Maartje J. Hooning, Antoinette Hollestelle, Frans B. L. Hogervorst, Julia Hentschel, Mohamed Helmy, Karl Hackmann, Jessica, Christian Gieger, Willemina R. R. Geurts-Giele, Andrea Gehrig, Christoph Engel, Alison M. Dunning, Michael R. Dufault, Sten Cornelissen, Sara Carvalho, Shelley Bull, Manjeet K. Bolla, Riccardo Berutti, Margreet Ausems, Norbert Arnold, Janine Altmüller, Jamie Allen, Muriel A. Adank, Audrey Lemaçon, Frédéric Fournier, Maxime Vallée, Penny Soucy, Annie-Claude Collin-Deschesnes, Stéphane Dubois, Bing-Jian Feng, Arnaud Droit, Corinna Ernst, Charles Joly-Beauparlant, Nana Weber-Lassalle, Martine Dumont, Cancers, 2022, 10.3390/cancers14143363
  • Systematic mixed-methods reviews are not ready to be assessed with the available tools, , J Clin Epidemiol, 2011, 10.1016/j.jclinepi.2011.01.002
  • Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals, , HGG Adv, 2021, 10.1016/j.xhgg.2021.100041
  • Stimulation of growth hormone release and synthesis by estrogens in rat anterior pituitary cells in culture, , Endocrinology, 1986, 10.1210/endo-119-5-2004
  • Glucocorticoids enhance activation of the human type II 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase gene, , J Steroid Biochem Mol Biol, 2002, 10.1016/s0960-0760(02)00147-4
  • The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds, , Nat Genet, 1996, 10.1038/ng0396-333
  • Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation, , Nat Commun, 2014, 10.1038/ncomms5999
  • PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS, , J Med Genet, 2016, 10.1136/jmedgenet-2016-103839
  • Type I protein C deficiency in French Canadians: evidence of a founder effect and association of specific protein C gene mutations with plasma protein C levels, , Thromb Haemost, 1998
  • Genetic predisposition to ductal carcinoma in situ of the breast, , Breast Cancer Res, 2016, 10.1186/s13058-016-0675-7
  • Personalized early detection and prevention of breast cancer: ENVISION consensus statement, , Nat Rev Clin Oncol, 2020, 10.1038/s41571-020-0388-9
  • Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers, , PLoS One, 2015, 10.1371/journal.pone.0120020
  • Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families, , J Hum Genet, 2013, 10.1038/jhg.2012.127
  • Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families, , Int J Cancer, 2008, 10.1002/ijc.23058
  • Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk, , Int J Cancer, 2020, 10.1002/ijc.32542
  • On the readiness of physicians for pharmacogenomics testing: an empirical assessment, , Pharmacogenomics J, 2018, 10.1038/tpj.2017.22
  • Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs, , Mol Cell Endocrinol, 1985, 10.1016/0303-7207(85)90131-5
  • Rapid restriction fragment analysis for screening four point mutations of the low-density lipoprotein receptor gene in French Canadians, , Hum Mutat, 1995, 10.1002/humu.1380060307
  • Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus, , Neurosci Lett, 1991, 10.1016/0304-3940(91)90903-7
  • MicroRNA related polymorphisms and breast cancer risk, , PLoS One, 2014, 10.1371/journal.pone.0109973
  • Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges, , Fam Cancer, 2006, 10.1007/s10689-005-2570-8
  • Potent antagonism between estrogens and androgens on GCDFP-15 expression and cell growth in the ZR-75-1 human breast cancer cells, , Ann N Y Acad Sci, 1990, 10.1111/j.1749-6632.1990.tb17805.x
  • Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types, , Cancer Discov, 2016, 10.1158/2159-8290.Cd-15-1227
  • Genetic testing, physicians and the law: will the tortoise ever catch up with the hare?, , Ann Health Law, 2010
  • Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate, , Mol Cell Endocrinol, 1990, 10.1016/0303-7207(90)90190-j
  • Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium, , Cancer Epidemiol Biomarkers Prev, 2020, 10.1158/1055-9965.Epi-19-0546
  • Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers, , Breast Cancer Res, 2014, 10.1186/s13058-014-0492-9
  • Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study, , J Natl Cancer Inst, 2019, 10.1093/jnci/djy132
  • Impact de l'intracrinologie dans la thérapeutique et le prévention des cancers du sein et de la prostate, et de la ménopause, , Rev Fr Endocrinol Clin, 1999
  • Sources d'androgènes chez l'homme et traitement hormonal du cancer de la prostate (Chapter 16), , Endocrinologie Masculine, 1996
  • Prediction of breast cancer risk based on profiling with common genetic variants, , J Natl Cancer Inst, 2015, 10.1093/jnci/djv036
  • A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor, , Nucleic Acids Res, 2019, 10.1093/nar/gkz780
  • Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium, Douglas F. Easton, Antonis C. Antoniou, Thea M. Mooij, Flora E. van Leeuwen, David Goldgar, Mary Beth Terry, Kelly-Anne Phillips, Roger L. Milne, Rita K. Schmutzler, Jacques Simard, Johanna Rantala, Annelie Augustinsson, Yen Tan, Christian F. Singer, Anna Jakubowska, Anne-Marie Gerdes, Edith Olah, Dita Berkova, Lenka Foretova, Ana Osorio, Miguel de la Hoya, Melissa C. Southey, Mary B. Daly, Irene L. Andrulis, Sarah V. Colonna, Jennie Murray, Saba Sharif, Hannah Musgrave, Katie Snape, Vishakha Tripathi, Louise Izatt, Jackie Cook, Fiona Lalloo, Marc Tischkowitz, D. Gareth Evans, Marijke R. Wevers, Irma van de Beek, Encarnacion B. Gomez Garcia, Margreet G. E. M. Ausems, Marjanka K. Schmidt, Lucie Salle, Véronique Mari, Pascaline Berthet, Jean-Pierre Fricker, Christine Lasset, Emmanuelle Mouret-Fourme, Catherine Noguès, Nadine Andrieu, John L. Hopper, Esther M. John, Karin Kast, Breast Cancer Research, 2023, 10.1186/s13058-023-01673-w
  • Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus, , Nat Commun, 2016, 10.1038/ncomms12675
  • A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk, , Cancer Res, 2018, 10.1158/0008-5472.Can-18-0951
  • Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study, , Am J Obstet Gynecol, 2021, 10.1016/j.ajog.2021.01.014
  • Multiple factors controlling ACTH secretion at the anterior pituitary level, , Ann N Y Acad Sci, 1987, 10.1111/j.1749-6632.1987.tb24953.x
  • Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells, , Mol Endocrinol, 2000, 10.1210/mend.14.2.0416
  • Gonadotropin-releasing hormone agonists in the treatment of prostate cancer, , Endocr Rev, 2005, 10.1210/er.2004-0017
  • Regulating cancer risk prediction: legal considerations and stakeholder perspectives on the Canadian context, Yann Joly, Jacques Simard, Michel Dorval, Hermann Nabi, Michael Wolfson, Bartha M. Knoppers, Michael Lang, Ma’n H. Zawati, Terese Knoppers, Palmira Granados Moreno, Human Genetics, 2023, 10.1007/s00439-023-02576-8
  • Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores, , J Clin Oncol, 2017, 10.1200/jco.2016.69.4935
  • Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7, , Genomics, 1992, 10.1016/s0888-7543(05)80284-8
  • Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA), , Br J Cancer, 2009, 10.1038/sj.bjc.6605416
  • Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3, , Breast Cancer Res Treat, 2017, 10.1007/s10549-016-4018-2
  • DHEA and peripheral androgen and estrogen formation: intracinology, , Ann N Y Acad Sci, 1995, 10.1111/j.1749-6632.1995.tb17369.x
  • Linkage analysis of 26 Canadian breast and breast-ovarian cancer families, , Hum Genet, 1995, 10.1007/bf00223867
  • Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2, , Nat Commun, 2019, 10.1038/s41467-019-13194-2
  • Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians, , J Lipid Res, 2003, 10.1194/jlr.M200479-JLR200
  • No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families, , Curr Oncol, 2017, 10.3747/co.24.3759
  • Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics, , Am J Hum Genet, 2000, 10.1086/302807
  • Mendelian randomisation study of smoking exposure in relation to breast cancer risk, , Br J Cancer, 2021, 10.1038/s41416-021-01432-8
  • Genetic linkage mapping of HSD3B1 and HSD3B2 encoding human types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase close to D1S514 and the centromeric D1Z5 locus, , Cytogenet Cell Genet, 1995, 10.1159/000133938
  • Detection and functional characterization of the novel missense mutation Y254D in type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) gene of a female patient with nonsalt-losing 3 beta HSD deficiency, , J Clin Endocrinol Metab, 1994, 10.1210/jcem.78.3.8126127
  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes, , Am J Hum Genet, 2019, 10.1016/j.ajhg.2018.11.002
  • Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer, , Cancer Epidemiol Biomarkers Prev, 2005, 10.1158/1055-9965.Epi-04-0202
  • Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations, , Atherosclerosis, 1999, 10.1016/s0021-9150(98)00267-6
  • Characteristics of the desensitization of growth hormone and cyclic AMP responses to growth hormone-releasing factor and prostaglandin E2 in rat anterior pituitary cells in culture, , Mol Cell Endocrinol, 1986, 10.1016/0303-7207(86)90072-9
  • Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey, , Mol Cell Endocrinol, 1994, 10.1016/0303-7207(94)90056-6
  • Variations in Rates: why we need clinical management recommendations, , Open Med, 2007
  • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer, , Nat Genet, 2017, 10.1038/ng.3826
  • Regulation of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase expression and activity in the hypophysectomized rat ovary: interactions between the stimulatory effect of human chorionic gonadotropin and the luteolytic effect of prolactin, , Endocrinology, 1990, 10.1210/endo-127-6-2726
  • Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1 alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells, , Int J Cancer, 1995, 10.1002/ijc.2910620614
  • Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer, , J Hum Genet, 2009, 10.1038/jhg.2009.6
  • Characterization of the structure-activity relationships of rat types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5 -delta 4 isomerase by site-directed mutagenesis and expression in HeLa cells, , J Biol Chem, 1991
  • Response of symbiotic endomycorrhizal fungi to estrogens and antiestrogens, , Mol Plant Microbe Interact, 1997
  • Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families, , Hum Genet, 2005, 10.1007/s00439-005-1297-9
  • New concepts on the androgen sensitivity of prostate cancer, , Prog Clin Biol Res, 1987
  • Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity, , J Invest Dermatol, 1995, 10.1111/1523-1747.ep12324390
  • Using the impact of event scale to evaluate distress in the context of genetic testing for breast cancer susceptibility, , Psychol Rep, 2006, 10.2466/pr0.98.3.873-881
  • Molecular genetics, structure-function relationships and tissue-specific expression and tissue-specific expression and regulation of the 3b-hydroxysteroid dehydrogenase/D5-D4 isomerase gene family, , Function of somatic cells in the testis, 1994
  • rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk, , Sci Rep, 2016, 10.1038/srep36874
  • Life events may contribute to family communication about cancer risk following BRCA1/2 testing, , J Genet Couns, 2013, 10.1007/s10897-012-9531-9
  • 17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes, , J Mol Endocrinol, 1999, 10.1677/jme.0.0230001
  • Localization of peptide gene expression by in situ hybridization at the electron microscopic level, , Gene probes, 1989
  • Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study, , Breast Cancer Res, 2014, 10.1186/bcr3662
  • High risk genes predisposing to prostate cancer development-do they exist?, , Prostate Cancer Prostatic Dis, 2000, 10.1038/sj.pcan.4500478
  • Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), , Cancer Epidemiol Biomarkers Prev, 2012, 10.1158/1055-9965.Epi-11-0775
  • Androgens in post-menopause, , Riv Ostet Ginecol Prat Med Perinat, 1991
  • CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers, , Br J Cancer, 2021, 10.1038/s41416-020-01185-w
  • Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus, , Breast Cancer Res, 2016, 10.1186/s13058-016-0718-0
  • BRCA1 gene expression in reproductive and endocrine tissues in adult cynomolgus monkey, , Ann N Y Acad Sci, 1998, 10.1111/j.1749-6632.1998.tb10828.x
  • The Passing of Dr. Fernand Labrie (1937-2019): The legacy of excellence in science, , J Steroid Biochem Mol Biol, 2019, 10.1016/j.jsbmb.2019.02.005
  • Variations of pre-proNPY mRNA in the arcuate nucleus during the rat estrous cycle, , Neuroreport, 1992, 10.1097/00001756-199203000-00009
  • BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors, , Genet Med, 2019, 10.1038/s41436-018-0406-9
  • Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families, , Oncotarget, 2017, 10.18632/oncotarget.20219
  • Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers, , Can Assoc Radiol J, 2016
  • Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family, , Endocr Rev, 2005, 10.1210/er.2002-0050
  • Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry, , Cancer Causes Control, 2016, 10.1007/s10552-016-0741-6
  • A candidate prostate cancer susceptibility gene at chromosome 17p, , Nat Genet, 2001, 10.1038/84808
  • Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells, , Cancer Res, 1991
  • Les enjeux éthiques du partage des résultats de recherche: l'expérience d'INHERIT BRCAS, , La recherche en génétique et en génomique : droits et responsabilités, 2005
  • Combination therapy with the antiandrogen Flutamide and the LHRH agonist [D-Trp6, des-Gly-NH210]LHRH ethylamide in prostate cancer: rationale and 5-year clinical experience, , Molecular biology of brain and endocrine peptidergic systems, 1988
  • Binding of a member of the NF1 family of transcription factors to two distinct cis-acting elements in the promoter and 5'-flanking region of the human cellular retinol binding protein 1 gene, , Mol Endocrinol, 1994, 10.1210/mend.8.6.7935489
  • Purification, cloning, complementary DNA structure, and predicted amino acid sequence of human estradiol 17 beta-dehydrogenase, , Ann N Y Acad Sci, 1990, 10.1111/j.1749-6632.1990.tb34281.x
  • Publisher Correction: Shared heritability and functional enrichment across six solid cancers, , Nat Commun, 2019, 10.1038/s41467-019-12095-8
  • Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics., Kang D, Soo Teo, Pharoah PDP, Dunning AM, Zheng Y, Yamaji T, Wu AH, Tsugane S, Tseng C, Takahashi A, Spinelli JJ, Shin MH, Shen CY, Park MH, Park B, Noh DY, Muir K, Matsuo K, Matsuda K, Mariapun S, Low SK, Lophatananon A, Li J, Kwong A, Allison Kurian, Kim MK, Kasuga Y, John EM, Iwata H, Iwasaki M, Ito H, WEANG KEE HO, Hartman M, Gao YT, Chan TL, Aronson KJ, Tao R, Li B, Guo X, Wang Q, Dennis J, Bolla MK, Park SK, Kubo M, Choi JY, Kweon SS, Cai Q, Yang Y, Shu X, Ping J, Jia G, American journal of human genetics, 2022, 10.1016/j.ajhg.2022.10.011
  • Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort, , Int J Cancer, 2019, 10.1002/ijc.31841
  • Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators, , Am J Hum Genet, 1998, 10.1086/301745
  • Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants, , Genet Med, 2020, 10.1038/s41436-020-0862-x
  • An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA), , Breast Cancer Res, 2007, 10.1186/bcr1670
  • Effect of the Women's Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testing, , Cancer Epidemiol Biomarkers Prev, 2007, 10.1158/1055-9965.Epi-06-0340
  • Lessons learned and challenges posed in cancer genetics. Introduction, , J Intern Med, 2013, 10.1111/joim.12129
  • Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History, , J Natl Cancer Inst, 2021, 10.1093/jnci/djaa127
  • Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase family, , Mol Cell Endocrinol, 1994, 10.1016/0303-7207(94)90066-3
  • Description of the International Consortium For Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13, , Prostate, 2005, 10.1002/pros.20198
  • Family communication following BRCA1/2 genetic testing: a close look at the process, , J Genet Couns, 2013, 10.1007/s10897-012-9559-x
  • Potent stimulatory effect of interleukin-1 alpha on apolipoprotein D and gross cystic disease fluid protein-15 expression in human breast-cancer cells, , Int J Cancer, 1994, 10.1002/ijc.2910590319
  • Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers, , Hum Mol Genet, 2011, 10.1093/hmg/ddr226
  • Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population, , Mol Oncol, 2013, 10.1016/j.molonc.2012.08.002
  • Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells, , Cancer Res, 1991
  • Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element, , Am J Hum Genet, 2021, 10.1016/j.ajhg.2021.05.013
  • Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers, , J Natl Cancer Inst, 2011, 10.1093/jnci/djq494
  • Large-scale genotyping identifies 41 new loci associated with breast cancer risk, , Nat Genet, 2013, 10.1038/ng.2563
  • Structure function and tissue-specific gene expression of 3beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzyme in classical and peripheral intracrine steroidogenic tissues, , J Steroid Biochem Mol Biol, 1992
  • Localization and regulation of expression of the FAR-17A gene in the hamster flank organs, , J Invest Dermatol, 1996, 10.1111/1523-1747.ep12297867
  • Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions, , Genet Epidemiol, 2014, 10.1002/gepi.21771
  • No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study, , Breast Cancer Res Treat, 2009, 10.1007/s10549-008-0064-8
  • Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers, , Breast Cancer Res, 2012, 10.1186/bcr3121
  • Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience, , Cancer Metastasis Rev, 1987, 10.1007/bf00047470
  • The challenge of connecting genomic knowledge to disease prevention: a Canadian integrative experience, , Community genetics: Past and future, 2002
  • Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries, , Int J Epidemiol, 2021, 10.1093/ije/dyab036
  • Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression, , Am J Hum Genet, 2015, 10.1016/j.ajhg.2015.05.002
  • A response to "Personalised medicine and population health: breast and ovarian cancer", , Hum Genet, 2019, 10.1007/s00439-019-01984-z
  • Effect of luteinizing hormone releasing hormone (LHRH) and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide on alpha-subunit and LH beta messenger ribonucleic acid levels in rat anterior pituitary cells in culture, , Mol Endocrinol, 1988, 10.1210/mend-2-6-521
  • Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population, , J Genet Couns, 2008, 10.1007/s10897-008-9150-7
  • Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk, , Sci Rep, 2020, 10.1038/s41598-020-65665-y
  • Structure-function relationships of 3 beta-hydroxysteroid dehydrogenase: contribution made by the molecular genetics of 3 beta-hydroxysteroid dehydrogenase deficiency, , Steroids, 1997, 10.1016/s0039-128x(96)00178-x
  • Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate, , Endocrinology, 1989, 10.1210/endo-124-6-2745
  • Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2, , Breast Cancer Res, 2011, 10.1186/bcr3052
  • Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers, , Nat Commun, 2020, 10.1038/s41467-020-16483-3
  • Androgens, DHEA and breast cancer, , Androgens and reproductive aging, 2006
  • Characterization of macaque 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase: structure and expression in steroidogenic and peripheral tissues in primate, , Mol Cell Endocrinol, 1991, 10.1016/0303-7207(91)90224-g
  • DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging, , Steroids, 1998, 10.1016/s0039-128x(98)00007-5
  • Mechanisms of action of estrogens and antiestrogens, , The menopause at the millennium: proceedings of the 9th World Congress on the Menopause, 2000
  • Atrial natriuretic factor-induced cGMP accumulation in rat anterior pituitary cells in culture is not coupled to hormonal secretion, , Regul Pept, 1986, 10.1016/0167-0115(86)90068-6
  • Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers, , Hum Mutat, 2012, 10.1002/humu.22025
  • Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium, , Hum Genet, 2016, 10.1007/s00439-015-1616-8
  • Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells, , Endocrinology, 1993, 10.1210/endo.132.1.8380373
  • Multihormonal regulation of dehydroepiandrosterone sulfotransferase messenger ribonucleic acid levels in adult rat liver, , Endocrinology, 1994, 10.1210/endo.134.4.8137732
  • Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36. The CRC/BPG UK Familial Prostate Cancer Study Coordinators and Collaborators. The EU Biomed Collaborators, , J Med Genet, 2000, 10.1136/jmg.37.12.947
  • Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility, , Nutr Cancer, 2006, 10.1207/s15327914nc5402_1
  • Molecular basis of human 3 beta-hydroxysteroid dehydrogenase deficiency, , J Steroid Biochem Mol Biol, 1995, 10.1016/0960-0760(95)00043-y
  • A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers, , Cancer Epidemiol Biomarkers Prev, 2012, 10.1158/1055-9965.Epi-12-0229
  • A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty, , J Clin Endocrinol Metab, 2000, 10.1210/jcem.85.5.6581
  • Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer, , J Mol Endocrinol, 2008, 10.1677/jme-07-0101
  • Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation, , Genet Med, 2016, 10.1038/gim.2015.135
  • Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters, , Urology, 1997, 10.1016/s0090-4295(97)00029-0
  • Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene, , Nat Genet, 1992, 10.1038/ng0792-239
  • Organizational challenges to equity in the delivery of services within a new personalized risk-based approach to breast cancer screening, , New Genet Soc, 2019
  • Conversion of precursor adrenal steroids into potent androgens in peripheral tissue, , Early stage prostate cancer: diagnosis and choice of treatment: proceedings of the International Symposium on Diagnosis and Treatment of Early Stage Prostate Cancer, held in Quebec City, Canada, on 3 October 1988, 1989
  • Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control, , Genes (Basel), 2019, 10.3390/genes10030186
  • Parallel solid-phase synthesis of a model library of 7alpha-alkylamide estradiol derivatives as potential estrogen receptor antagonists, , Bioorg Med Chem Lett, 1999, 10.1016/s0960-894x(99)00487-4
  • Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the "Angelina Jolie Effect"?, , Am J Prev Med, 2017, 10.1016/j.amepre.2017.05.016
  • The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21, , Hum Mol Genet, 1994, 10.1093/hmg/3.9.1679
  • Personalized medicine and access to health care: potential for inequitable access?, , Eur J Hum Genet, 2013, 10.1038/ejhg.2012.149
  • Two truncating variants in FANCC and breast cancer risk, , Sci Rep, 2019, 10.1038/s41598-019-48804-y
  • Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA, , Hum Mol Genet, 1993, 10.1093/hmg/2.8.1193
  • DSNetwork: An Integrative Approach to Visualize Predictions of Variants' Deleteriousness, , Front Genet, 2019, 10.3389/fgene.2019.01349
  • Estimated potency of Casodex: a problematic design, , Urology, 1997
  • Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro, , Int J Cancer, 1997, 10.1002/(sici)1097-0215(19970926)73:1<104::aid-ijc16>3.0.co;2-g
  • A common ancestor for mammalian 3 beta-hydroxysteroid dehydrogenase and plant dihydroflavonol reductase, , Biochem J, 1990, 10.1042/bj2690558
  • Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium, , Prostate, 2003, 10.1002/pros.10301
  • Structure, regulation and role of 3 beta-hydroxysteroid dehydrogenase, 17 beta-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues, , Baillieres Clin Endocrinol Metab, 1994, 10.1016/s0950-351x(05)80261-7
  • Generation of a transcription map at the HSD17B locus centromeric to BRCA1 at 17q21, , Genomics, 1995, 10.1006/geno.1995.1185
  • Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer, , Nat Commun, 2019, 10.1038/s41467-018-08053-5

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2009
  • Anne-Laure Renault - Maîtrise avec mémoire - 2014/01
  • Martin Leclerc - Doctorat - 2016/01
  • Mandy Ducy - Maîtrise avec mémoire - 2018/09
  • Audrey Lemaçon - Doctorat - 2019/01
  • Jolyane Blouin-Bougie - Doctorat - 2023/01

Encadrement d'étudiant(e)s pour les programmes suivants :

Disponibilité d'encadrement d'étudiant(e)s

Ce (cette) professeur(e) est présentement à la recherche d'étudiant(e)s.

Envoyer un courriel
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.
Mettre à jour mon profil de professeur(e)